The global sleep apnea implants market is expected to grow from USD 317.1 million in 2023 to USD 1,158.1 million by 2033, at ...

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on January 13.Stay Ahead of the ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

Sleep is often a huge challenge for many people, and in several cases, people do need some sort of medical intervention.

Inspire Medical Systems shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 72 to 81.

The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug ...

Wasatch Global Investors, an asset management company, released its “Wasatch Small Cap Growth Strategy” third-quarter 2024 ...

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA) in ...

Sleep apnea is truly exhausting: Restless nights, daytime fatigue, and then there’s the battle to find a treatment that works for you. The good news is that, for those with mild to moderate sleep ...

As Zepbound becomes available for this new indication, its role in addressing the interconnected challenges of obesity and sleep apnea may redefine treatment strategies for millions struggling ...